

Daniel M Hartung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2723154/publications.pdf>

Version: 2024-02-01

86
papers

2,148
citations

236925

25
h-index

265206

42
g-index

86
all docs

86
docs citations

86
times ranked

2944
citing authors

#	ARTICLE	IF	CITATIONS
1	The cost of multiple sclerosis drugs in the US and the pharmaceutical industry. <i>Neurology</i> , 2015, 84, 2185-2192.	1.1	229
2	Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications. <i>Annals of Internal Medicine</i> , 2014, 160, 477.	3.9	173
3	Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review. <i>Annals of Internal Medicine</i> , 2013, 158, 114.	3.9	99
4	Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. <i>Neurotherapeutics</i> , 2017, 14, 1018-1026.	4.4	72
5	Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 30.	2.6	67
6	Clinical implications of an accurate problem list on heart failure treatment. <i>Journal of General Internal Medicine</i> , 2005, 20, 143-147.	2.6	62
7	The Economic Burden of Multiple Sclerosis in the United States. <i>Neurology</i> , 2022, 98, .	1.1	61
8	Rates of Adverse Events of Long-Acting Opioids in a State Medicaid Program. <i>Annals of Pharmacotherapy</i> , 2007, 41, 921-928.	1.9	54
9	Impact of a Medicaid Copayment Policy on Prescription Drug and Health Services Utilization in a Fee-for-Service Medicaid Population. <i>Medical Care</i> , 2008, 46, 565-572.	2.4	54
10	Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 113-121.	2.8	49
11	Pharmacistsâ€™ Role in Opioid Safety: A Focus Group Investigation. <i>Pain Medicine</i> , 2018, 19, 1799-1806.	1.9	49
12	Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden. <i>Drug and Alcohol Dependence</i> , 2021, 224, 108729.	3.2	46
13	Overview of clinical research design. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 398-408.	1.0	44
14	Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin. <i>JAMA Network Open</i> , 2018, 1, e180482.	5.9	44
15	The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2015, 4, 21.	5.3	43
16	Pharmacist Provision of Hormonal Contraception in the Oregon Medicaid Population. <i>Obstetrics and Gynecology</i> , 2019, 133, 1231-1237.	2.4	42
17	Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid Costs. <i>Obstetrics and Gynecology</i> , 2019, 133, 1238-1246.	2.4	40
18	Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care medicaid population. <i>Clinical Therapeutics</i> , 2004, 26, 1518-1532.	2.5	37

#	ARTICLE	IF	CITATIONS
19	A Chronic Opioid Therapy Dose Reduction Policy in Primary Care. <i>Substance Abuse</i> , 2016, 37, 141-147.	2.3	36
20	Risk of Hospitalization for Heart Failure Associated with Thiazolidinedione Therapy: A Medicaid Claims-Based Case-Control Study. <i>Pharmacotherapy</i> , 2005, 25, 1329-1336.	2.6	35
21	Effect of Automated Prescription Drug Monitoring Program Queries on Emergency Department Opioid Prescribing. <i>Annals of Emergency Medicine</i> , 2018, 71, 337-347.e6.	0.6	34
22	Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. <i>Pain</i> , 2022, 163, 83-90.	4.2	33
23	Health economics of disease-modifying therapy for multiple sclerosis in the United States. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642098703.	3.5	31
24	Trends and Characteristics of US Medicare Spending on Repository Corticotropin. <i>JAMA Internal Medicine</i> , 2017, 177, 1680.	5.1	28
25	Patterns of Atypical Antipsychotic Subtherapeutic Dosing Among Oregon Medicaid Patients. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1540-1547.	2.2	27
26	Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 607.	7.4	26
27	Effects of a prior authorization policy for extended-release/long-acting opioids on utilization and outcomes in a state Medicaid program. <i>Addiction</i> , 2018, 113, 1651-1660.	3.3	24
28	Effect of a High Dosage Opioid Prior Authorization Policy on Prescription Opioid Use, Misuse, and Overdose Outcomes. <i>Substance Abuse</i> , 2018, 39, 239-246.	2.3	24
29	Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 66-75.	1.9	23
30	The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program. <i>Psychiatric Services</i> , 2016, 67, 397-404.	2.0	23
31	Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 568-576.	1.5	22
32	A pilot study evaluating alternative approaches of academic detailing in rural family practice clinics. <i>BMC Family Practice</i> , 2012, 13, 129.	2.9	21
33	Rural-Urban Differences in Chronic Disease and Drug Utilization in Older Oregonians. <i>Journal of Rural Health</i> , 2016, 32, 269-279.	2.9	21
34	Impact of Hospital "Best Practice" Mandates on Prescription Opioid Dispensing After an Emergency Department Visit. <i>Academic Emergency Medicine</i> , 2017, 24, 905-913.	1.8	21
35	Interventions to Improve Pharmacological Adherence Among Adults With Psychotic Spectrum Disorders and Bipolar Disorder: A Systematic Review. <i>Psychosomatics</i> , 2017, 58, 101-112.	2.5	21
36	Assessment of Opioid Prescribing Patterns in a Large Network of US Community Health Centers, 2009 to 2018. <i>JAMA Network Open</i> , 2020, 3, e2013431.	5.9	21

#	ARTICLE	IF	CITATIONS
37	Generic Substitution of Lamotrigine Among Medicaid Patients with Diverse Indications. <i>CNS Drugs</i> , 2012, 26, 707-716.	5.9	20
38	Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients. <i>Neurology: Clinical Practice</i> , 2016, 6, 177-182.	1.6	20
39	Effect of Drug Sample Removal on Prescribing in a Family Practice Clinic. <i>Annals of Family Medicine</i> , 2010, 8, 402-409.	1.9	19
40	Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1053-1060.	1.9	19
41	Variations in prescription drug monitoring program use by prescriber specialty. <i>Journal of Substance Abuse Treatment</i> , 2018, 94, 35-40.	2.8	19
42	Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. <i>Health Affairs</i> , 2019, 38, 303-312.	5.2	18
43	Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D. <i>Diabetes Care</i> , 2020, 43, e50-e51.	8.6	17
44	Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1422-1430.	3.0	16
45	Role of practice-based research networks in comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 45-55.	1.4	14
46	Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1285.	9.0	14
47	Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102404.	2.0	14
48	Commentary Article: Study Protocol for the Respond to Prevent Study: A Multi-State Randomized Controlled Trial to Improve Provision of Naloxone, Buprenorphine and Nonprescription Syringes in Community Pharmacies. <i>Substance Abuse</i> , 2022, 43, 901-905.	2.3	13
49	Risk factors associated with linezolid-nonsusceptible enterococcal infections. <i>American Journal of Infection Control</i> , 2012, 40, 886-887.	2.3	12
50	The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses. <i>JAMA Neurology</i> , 2015, 72, 739.	9.0	12
51	Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?. <i>American Journal of Kidney Diseases</i> , 2019, 74, 256-262.	1.9	12
52	Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis. <i>Neurology</i> , 2020, 94, e1407-e1414.	1.1	12
53	Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 3188-3196.	2.6	11
54	Use of Administrative Data to Identify Off-Label Use of Second-Generation Antipsychotics in a Medicaid Population. <i>Psychiatric Services</i> , 2013, 64, 1236-1242.	2.0	10

#	ARTICLE	IF	CITATIONS
55	The Geographic Impact of Buprenorphine Expansion to Nurse Practitioner Prescribers in Oregon. <i>Journal of Rural Health</i> , 2022, 38, 112-119.	2.9	10
56	An Evaluation Of Oregon's Evidence-Based Practitioner-Managed Prescription Drug Plan. <i>Health Affairs</i> , 2006, 25, 1423-1432.	5.2	9
57	Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1411.	9.0	9
58	Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 450-455.e3.	1.5	9
59	Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 87-94.	1.9	8
60	Qualitative study on the price of drugs for multiple sclerosis. <i>Neurology</i> , 2020, 94, e368-e375.	1.1	8
61	Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 28.	4.2	7
62	Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e237-e241.	1.5	7
63	A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations. <i>Addictive Behaviors</i> , 2018, 86, 32-39.	3.0	6
64	Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 856-864.	0.9	6
65	Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs. <i>Neurology: Clinical Practice</i> , 2021, 11, 298-303.	1.6	6
66	Changes in Long-acting μ -agonist Utilization After the FDA's 2010 Drug Safety Communication. <i>Clinical Therapeutics</i> , 2015, 37, 114-123.e1.	2.5	5
67	Evaluation of an Interdisciplinary Controlled Substance Review Committee on Opioid Prescribing in a Community Health Center. <i>Pain Medicine</i> , 2020, 21, 1840-1846.	1.9	5
68	Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 395-399.	1.9	5
69	Decreasing Trends in Opioid Prescribing on Discharge to Hospice Care. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 1026-1033.	1.2	5
70	Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108615.	2.8	5
71	Does Prescription Opioid Shopping Increase Overdose Rates in Medicaid Beneficiaries?. <i>Annals of Emergency Medicine</i> , 2018, 71, 679-687.e3.	0.6	4
72	Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. <i>International Journal of MS Care</i> , 2022, 24, 90-97.	1.0	4

#	ARTICLE	IF	CITATIONS
73	A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1168-1174.	1.9	3
74	Exploring Patient Perceptions of Opioid Treatment Agreements in a Community Health Center Environment. <i>Pain Medicine</i> , 2021, 22, 970-978.	1.9	3
75	Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation. <i>Journal of Addiction Medicine</i> , 2021, 15, 130-133.	2.6	3
76	Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 78-83.	5.0	2
77	Elephant in the room. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e11-e11.	0.9	2
78	The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102554.	2.0	2
79	Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications. <i>JAMA Internal Medicine</i> , 2022, 182, 206.	5.1	2
80	One practice's experiment in refusing detail rep visits. <i>Journal of Family Practice</i> , 2011, 60, E1-6.	0.2	2
81	Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021. <i>JCO Oncology Practice</i> , 2022, 18, e1574-e1586.	2.9	2
82	Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program. <i>Neurology: Clinical Practice</i> , 2022, 12, 36-42.	1.6	1
83	Building Oregon Data: Short-Term Incidence of Sequelae of Chronic Liver Disease in Medicaid Patients Infected With Hepatitis C Virus. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
84	Uses of H.P. Acthar Gel in the Clinical Setting—Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 583.	5.1	0
85	The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, 5.	2.2	0
86	Evaluation of a Medicaid performance improvement project to reduce high-dose opioid prescriptions. <i>BMC Health Services Research</i> , 2022, 22, 68.	2.2	0